Yashvin Onkarappa Mangala, MD

66 posts

Yashvin Onkarappa Mangala, MD banner
Yashvin Onkarappa Mangala, MD

Yashvin Onkarappa Mangala, MD

@MDHemeonc

Heme/Onc and Internal Medicine trained @RWMCIM

Albuquerque, NM Katılım Kasım 2022
233 Takip Edilen113 Takipçiler
Yashvin Onkarappa Mangala, MD retweetledi
Andres Gomez
Andres Gomez@GomezDLeonMD·
The 2025 ASH guidelines for older adults with AML are now out! An honor to contribute alongside leaders in the field and to represent patients and physicians from Latin America and other LMICs. I never imagined having the opportunity to be part of something like this! 🤯@ASH_hematology ashpublications.org/bloodadvances/…
Andres Gomez tweet media
English
5
45
258
13K
Yashvin Onkarappa Mangala, MD retweetledi
Héctor A. Vaquera
Héctor A. Vaquera@VaqueraH_md·
🚨New paper out🚨 Glad to have collaborated in this project where we analyzed the usage of medical writing services in review articles in the top 10 highest ranked heme journals in the JCR IF list
Héctor A. Vaquera tweet media
English
3
11
47
4K
Yashvin Onkarappa Mangala, MD retweetledi
Talha Badar
Talha Badar@TalhaBadarMD·
#weekend_review 1/5 Brief overview of venetoclax+azacitidine for elderly #AML ineligible for intensive induction 🧵 #hemoncfellows #hemonctrainees #leusm #MedTwitter 1. Long term outcome from VIALE-A trial 2. Common toxicities and duration of therapy (7 vs 14 vs 28 days) 3. Differential outcome based on molecular signature 4. Venetoclax resistance and outcome post Ven failure
English
2
24
84
15.5K
Yashvin Onkarappa Mangala, MD retweetledi
Dr. Estela Rodriguez
Dr. Estela Rodriguez@Latinamd·
🚨Out today #ADRIATIC @NEJM one of the most impactful @ASCO -Lung presentations this year: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | ⚡️New standard of care⚡️ N=760 ▶️Durvalumab x2 yrs post CRT ⬆️mOS: 56 vs 33mos (HR 0.74) ⬆️mPFS: 16.6 vs 9.2 mos (HR 0.76) @DavidRSpigel #lcsm 🚨Out today #ADRIATIC @NEJM one of the most impactful @ASCO -Lung presentations this year: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | ⚡️New standard of care⚡️ N=760 ▶️Durvalumab x2 yrs post CRT ⬆️mOS: 56 vs 33mos (HR 0.74) ⬆️mPFS: 16.6 vs 9.2 mos (HR 0.76) @DavidRSpigel #lcsm nejm.org/doi/full/10.10…
Dr. Estela Rodriguez tweet media
English
1
33
72
7.7K
Yashvin Onkarappa Mangala, MD retweetledi
Nico Gagelmann
Nico Gagelmann@NicoGagelmann·
Tranfusion reaction algorithm
Nico Gagelmann tweet media
English
5
213
811
115.8K
Yashvin Onkarappa Mangala, MD retweetledi
𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM
A young doctor was r@ped & murdered 😭 Doctors are protesting (some aren't!!) The common man is opposing this protest or simply doesn't care 🤷🏻 The investigation has been botched up 😡 The evidence has been tampered with 😡 How is this acceptable? #MedTwitter 🇮🇳
English
15
125
457
10.5K
Pamela Contreras Chavez
Pamela Contreras Chavez@PamChMD·
The transition from being a fellow to be an attending is the hardest transition that I've ever had.....🔥🥲
English
7
1
28
4.7K
Yashvin Onkarappa Mangala, MD retweetledi
OncoAlert
OncoAlert@OncoAlert·
We are @OncoAlert 🚨
English
2
27
75
19.7K
Yashvin Onkarappa Mangala, MD
@NicoGagelmann Chronic lymphocytic leukemia! I recently saw a patient with CLL on Ibrutinib, whose labs showed a rising WBC count ~600K and a new onset thrombocytosis >1 million. Review of peripheral blood smear lead to an additional diagnosis!!
Yashvin Onkarappa Mangala, MD tweet media
English
3
0
11
3.9K
Nico Gagelmann
Nico Gagelmann@NicoGagelmann·
Patient with fever, fatigue and palpable lymph nodes. Diagnosis?
Nico Gagelmann tweet mediaNico Gagelmann tweet media
English
15
117
1.1K
184.2K